28 March 2017
News and Views
Links and Services
A study published ahead of print in the Alimentary Pharmacology & Therapeutics investigates the risk of infusion reactions associated with infliximab therapy for inflammatory conditions.
Infliximab is typically administered intravenously via 2- to 3-hour duration infusions.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors